Use of inhaled antibiotics among Danish patients with cystic fibrosis

Rikke Møller*, Bibi Uhre Nielsen, Daniel Faurholt-Jepsen, Terese Lea Katzenstein, Marianne Skov, Lue Katrine Drasbæk Philipsen, Tacjana Pressler, Helle Krogh Johansen, Tavs Qvist

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

6 Citationer (Scopus)
17 Downloads (Pure)

Abstract

Background: Inhaled antibiotics are an important part of cystic fibrosis (CF) airway disease management and should be individualized to fit the microorganism and match patient needs. To investigate the implementation of personalized treatment, this study mapped the use of different types of inhaled antibiotics and adherence patterns. Methods: We performed individual structured interviews in a cross-sectional study at the CF Centre in Copenhagen, Denmark. Patients with CF older than 15 years attending clinical consultations were included. Clinical data were obtained from centralized databases. Results: Among 149 participants, 107 (72%) had indication for treatment with inhaled antibiotics. In this group, 97 (91%) reported the use of inhaled antibiotics within the last 12 months. Change from one inhaled antibiotic to another during that period was reported by 31 (29%), and 17 (25%) with Pseudomonas aeruginosa had used off-label antibiotics. Adherence to a minimum of one daily dose of antibiotic was reported by 78%, while adherence to all daily doses was 28 percentage points lower. Skipping inhalations was due to side effects and doubt about the effect in less than 5% of cases. Conclusion: Change of inhaled antibiotics and use of off-label antibiotics for inhalation were common and side effects were a rare cause of nonadherence. This suggests satisfactory implementation of the principle of tailored antibiotic inhalation prescription in the Copenhagen CF population. Adherence to at least one daily inhalation dose was markedly higher than adherence to multiple daily inhalations.

OriginalsprogEngelsk
TidsskriftPediatric Pulmonology
Vol/bind57
Udgave nummer7
Sider (fra-til)1726-1734
Antal sider9
ISSN8755-6863
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
Tavs Qvist has received a research grant from Chiesi Pharmaceutici (20,000 EUR) for the purpose of financing salary for the PI of the study. Tavs Qvist has received unrelated grants from Rigshospitalets Research Council (250,000 EUR), The Danish CF Foundation: (42,000 EUR), and University of Queensland FORMAT Trial (26,000 EUR). Honorarium for educational activities outside the submitted work from the Chiesi Group (2000 EUR). Personal fees for lectures, scientific steering committee work or review from The Belgian CF Foundation (200 EUR), AstraZenica A/S (1075 EUR), Vertex (4317 EUR). Personal fees from Advisory Board outside the submitted work: Vertex (3558 EUR), Zambon Netherlands (3000 EUR), Chiesi Group (1300 EUR). The remaining authors declare no conflicts of interest.

Funding Information:
The authors would like to thank patients and staff at the Copenhagen Cystic Fibrosis Center. This study was supported by a grant from Chiesi Pharmaceutici, including funding of Rikke Møller's (PI) salary. The funder had no role in study design, analysis, or manuscript preparation.

Publisher Copyright:
© 2022 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.

Citationsformater